Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.


  1. Advanced Patent Search
Publication numberUS2868691 A
Publication typeGrant
Publication dateJan 13, 1959
Filing dateMar 21, 1956
Priority dateMar 21, 1956
Publication numberUS 2868691 A, US 2868691A, US-A-2868691, US2868691 A, US2868691A
InventorsIrving Porush, Maison George L
Original AssigneeRiker Laboratories Inc
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Self-propelling compositions for inhalation therapy containing a salt of isoproterenol or epinephrine
US 2868691 A
Abstract  available in
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

United States Patent SELF-PROPELLING COMPOSITIONS FOR INHALA-I TION THERAPY CONTAINING A SALT OF ISO- PROIERENOL R EPINEPHRIYE Claims. (Cl. 167-54) This invention relates to novel medicament-containing,

self-propelling compositions for inhalation'therapy.'-

A number of previous eflorts have been directed to the preparation of medicament-containing, pharmaceutical preparations for use in inhalation therapy. Thes'e preparations suffer from one or more shortcomings. In many cases they require cumbersome mechanical devices to dispense the medicament. Some of these devices employ a rubber airbulb to aspirate the medicament. This often requires substantial physical effort on the "part of the user. In other cases the vehicle for the medicament may possess irritating properties which mitigate against the use of the compositions for inhalation therapy where delicate mucous membranes may be aflected. In some cases Where a fixed dosage is required these'compositions are not conveniently dispensed in measured, constant amounts. For these reasons, as well as others, the benefits of inhalation therapy have not'been fully realized and progress in this mode of medication has lagged.

It is, therefore, one object of this invention to overcome the disadvantages of the prior art compositions invide a self-propelling therapeutic composition for inhalation therapy which maybe packaged with safety in suitable low pressure containers,;such as frangible containers, or in containers having a dispensing valve construction which will permit dispensing jmeasui'ed, constant doses of "the medicament.

Still another object of the present invention is to provide a stable therapeutic composition containing a liquified non-toxic propellent material which is not subject to erratic pressure variations and which imparts easily controlled pressures at room or ambient temperatures to the container in which the composition is stored and dispensed from.

Other objects will be apparent to those skilled in the .art from reading the description which follows.'

The self-propelling compositions of the present invention comprise a medicament dissolved in a non-toxic,

liquid propellant in thenature of a fluorinated or fluorochlorinated lower aliphatic hydrocarbon, preferably with the aid of a co-solvent for both the medicament and the a medicament in aerosol form for inhalation therapy.

'monochlorotrifluoromethane (Freon l3) "ice In carrying out the invention it is contemplated that the non-toxic, liquid propellant shall be a fluorinated or a fluorochlorinated lower saturated aliphatic hydrocarbon, and preferably a halogenated alkane containing not more than 2 carbon atoms and at least 1 fluorine atom, or mixtures thereof. The preferred halogenated lower alkane compounds may be represented generally by the formula C H Cl F wherein an integer less than 3, n is an integer or zero, yis aninteger or zero, and z is an integer, such that n+y+z=2m+2. The propellants shall possess a boiling point of less than F. at 760 mm. pressure. Examples of the propellantsare dichlorodifiuoromethane (Freon 12), dichlorotetrafluoroethane (Freon 114) CCIF CClF trichloromonofluoromethane (Freon 11), dichloromonofiuoromethane (Freon 21), and Propellants with improved vapor pressure characteristics may be obtained by using certain mixtures of these compounds, e. g., Freon 11 and Freon 12, or Freon 12 and Freon 114, For example, dichlorodifluoromethane, which has a vapor pressure of about 70 pounds per square inch .gauge and 1,2-dichloro-1,1,2,2-tetrafluoroethane (Freon 114), with a vapor pressure of about -13 pounds per square inch. gauge at 70 F., may be mixed in various proportions to form a propellant having an intermediate vapor pressure which is well suited for use in relatively low pressure containers.

It is desired that the vapor pressure of the propellant employed shall itself be between about 25 and 65 pounds per square inch gauge at 70 F., and preferably between about 30 and 40 pounds per square inch gauge at that temperature. A one-component propellant defined'for use in thecomposition was found to give a'composition with gaugepressures in the rangeof 55to 65 pounds per square inch at 70 F., which are usable safely with metal containers. The two-component propellants, such as equalweight mixtures of Freon 12 and "Freon 11, were found to give gauge pressures in the range of 2 0 to 40 pounds per square inch at 70 F., which are usable safely with specially reinforced glass containers.

The medicament employed in a composition according to this invention can be one which is therapeutically ef fective when administered'by inhalation and which may be brought into stable solution in any of the above defined liquified propellants, if necessary, with the aid of a cosolvent and/ or stabilizing substance. One type of medicament which can be employed satisfactorily is the vasoconstrictive amines and their acid-addition salts. However, other types of medicaments, such :as hormones, enzymes, alkaloids, steroids, analgesics, broncho-dilators,. antihistamines, 'antitussives, anginal preparations, antibiotics and sulfonamides and synergistic combinations of these,v

may be employed successfully. Examples of the medicaments which may be employed in producing the compositions of this invention are: isoproterenol hydrochloride [u-(isopropylaminomethyl) protocatechuyl alcohol], phenylephrine, epinephrine, ephedrine, narcotine, codeine, atropine, ergotamine, scopolamine, colchicine, cortisone and alkyl nitrites, such'as amyl nitrite or octyl nitrite.

The co-solvent maybe any liquid substance which assists in. dissolving the medicament in the liquified propellant and which is chemically inert to the medicament in the sense that it does not promote the decomposition of this substance. Suitable co-solvents are intermediate in polarity between the propellant and the medicament.

The co-solvents have the property of being a solvent for the medicament and soluble in the propellants prescribed for use in this invention. The co-solvent beside being chemically inert toward the medicament, should benontoxic andwithout undesirable effects on inhalation in the amount present in the aersol produced. The co-solvent shall have as low a boiling point as possible and prefer-. ably not higher than 212 F. at atmospheric pressure. Examples of satisfactory co-solvents include non-toxic loweralcohols and eth ers, e. g., ethanol, diethyl ether, chloroform, mixtures of ethanol and wate r, and mixtures of chloroform and ethanol.

The stabilizers or anti-oxidants which .may be employed are stronger reducing agents than the medicament and which are non-toxic, such as the alkali-metal bisu'lfites (sodium bisulfite), alkali-metal ascorbates (sodium ascorbate), ascorbic acid, nordihydroguaiaretic acid, 2- tertiarybutyl-4-hyd'roxy anisole, 3-tertiarybutyl-4-hydroxy anisole, butylated hydroxytoluene' (sold under the trademark Tenox BHT), ethylhydro-caffeate, etc. It is normallynot necessary to employ -a stabilizer in an amount in excess'of 0.25% by-weight ofthe composition.

One of the important features of this invcntionisthe discovery that the components 'ofthe compositions must be present within certain critical proportions, as otherwise the benefits of the invention are not obtained. One of the most important characteristics of a spray product is the spray pattern. Spray pattern involves the delivery rate, the particle size distribution and the spray angle. The spray pattern is affected by mechanical factors, e. g., valve construction and orifice size and shape, and by the characteristics of the composition, e. g., viscosity, vapor pressure, type and percentage of propellant. For example, where less than the minimum proportion of pro= pellant is employed, thecomposition lack-suificient propellent force and consequently the'inadequate aerosolization of the medicament results in a particle size distribution which is not efiiciently absorbed in-the' bronchioles and alveoli. Where more than the allowable maximum proportion of propellant is employed, the composition may become unstable during storage and-the medicament may precipitate from the composition. Also, thecompositions may develop undesirably high pressures.

into an open container. The open container and its contents are then cooled, preferably to a temperature below the boiling point of the propellant to be employed. A temperature of 25 F. is usually satisfactory. A measured quantity of the liquified propellant which also has been cooled below its boiling point is then introduced into the container and mixed with the solution already present. The quantities of the components introduced into the container are calculated to provide the desired concentration of each in the final composition. Without permitting the temperature of the container and its contents to-rise above the boilingpoint of the propellant, the container is sealed with a closure equipped with asuitable dispensing valve arrangement. Upon warming to room temperature the Q mnts of the container are mixed by agitation of the containerto insure complete solution of the medicament. The sealed container is then ready to dispense the composition and provide the medicament naerosol form- In prder more clearly to disclose the nature of the present invention, the following examples illustrating compositions in accordance with the invention will now be described. ;It sohuld be understood, however, that this is done, solely by way of example and is intended neither to delineate the scope of the invention nor limit the. ambitofthe appended claims. .In the examples which follow, the processdescribed above was employed. In the cxampleswhich follow and throughout the specification, the quantities of material are expressed in termsof One I of the essential characteristics of the compositions of'this I invention is that the medicament shall remain'dissolved and uniformly dispersed throughout the composition. To this end a co-solvent is often necessary in order to maintain the medicament in the dissolved, uniformly dispersed state, both at the time the compositions are prepared and during normal periodsand conditions of storage.

While the proportions of components may varysomewhat depending upon the specific medicament and liquificd propellant employed, in general it has been found desirable that the liquid propellant constitute at least about 50% by weight of the total composition upward to about 90%. It is preferred that the propellant constitute between about 55% or 60% and 80% by weight of the total composition. The amount and constitution of the co-solvent is largely dependent upon the solubility characteristics of the medicament employed. In most cases it has been found that satisfactory results are obtained where the co-solvent constitutes between about 5% or 10% and 40%, and preferably between abont 20% and 40%'-- v we hto the t a .cQmP s t Qn- .lf to! to ch c -so n s s e hanol; is us th int rnattern ,is affected, resulting-in a wetsprayor stream rather thanan aerosol cloud. The amout of medicament shall generally constitute from about 0.1% to 20%, and preferably from about 0.1% to 2% by weight of the'composition. Desirably the propellant makes-upthe difference 'betwen the proportions of medicamennco-solvent, stabilizer and 100%.

"The novel compositions of the-invention maybe-prepared and containers filled with them by-means of-the following process:

Asuitable measured quantity-of the medicament-is mixed with, and dissolved in, a measured amountof the co-solvent. .A stabilizer, if desired,- is added. A- measured quantity-zof the resultingsolution isythea ntra used percentages bysweight of the total composition.

E le

P s-.4 1 Isoproterenol H61 0.25 ate 11.

thane? wer I fluerqmohaa wn 211-.-

Example 2 v Percent Isoproterenol HCl 2 0.25 Water V i 1. 5 Ethanol (absolute) 33.25 Dichlorotetrafluoroethane (Freon 114) 40 Dichlorodifluorornethane (Freon 12) 25.0

Example 3 I Percent Isoproterenol l ICl ate Ethan We Trichloromonotiuoromethane (Freon 1-1) Example 6 g 1 V H Percent Narcotine v 1 Water 0.65 Ethanol (absolute) a 12.35 Chloroform 20.6 Dichlorodifiuorornethane (Freon 12) i f-'3 4.8 Dichlorotetrafluoroethane (Freon 114) 30.6

' -Example 7 p t A Percent Nicotine "1 Ethanol 95% T 34 Dicblorodifiuoromethane (Freon 12) 25 Dichlorotetrafluoroethane (Freon 114) 40 g 100 --Example 8 i r Q 'Percent Isoproterenol HCl 0.25 Water 1 1.5 Ethanol (absolute) 33.25 Dichlorotetrafluoroethane-(Freon- -1 14) 45.5 Dichlorodifluor ometha'ne (Freon 12.) 19.5

Example 9 I Percent Octyl nitrite 0.1- Ethanol 95% p 20 Dichlorotetrafluoroethane (Freon 114) 49.2 Dichlorodifluoromethane (Freon '12) 30.7

Example 10 I I I P ercent Atropine 0.1 Ethanol 95% a 9.9 Dichlorodifluoromethane (Freon 12) 45 Dichlorotetrafluoroethane (Freon 114) 45 1 100 Example 11 i t Percent Octyl nitrite 0.1 Ethanol 95 9.9 Dichlorotetrafiuoroethane .(Freon 114) 55.4 Dichlorodifiuoromethane (Freon 12) 34.6

Y 100 Example 12 Percent O ctyl nitrite 0.1 Diethyl ether 14.9 'Dichlorotetrafluoroethane (Freon 114) 45 Dichlorodifluoromethane (Freon 12) 40 Other medicaments than those employed in the above examples may be used, such as ergot-amine, scopolamine,

" colchicine, cortisone, amyl nitrite, etc.

' is liquified and cooled at 25 F., added to the chilled concentrate and mixed in. Keeping it at the same temperature, the mixture is measured into the container to 4' be filled and the container is sealed with a closure equipped with a suit-able dispensing valve arrangement. An alternative process, known as pressure filling," is paricularly suitable where the closure employed has, a special valve construction, for'example, that of the type disclosed .in U. S. Patent 2,721,010, issued Octoberl8, 1955. Such a valve' construction permits dispensing a measured dose of medicament'in aerosol form;

It is desirable to enclose the composition in accordance with this invention in apressure-tight container having a suitable outlet valve secured in an opening in the top wall of the container. With the compositions of the invention the pressure rangeis such that it is permissible to use glass bottles instead of metal containers. The compositions and the bottles are characterized by a clear, sparkling appearancewith the advantage that it is easy to observe when the'container is nearly empty. It is recommended for added safety that the glass bottles be coated with a plastic film, preferably clear. 'Aldip-tube of suitable material may be connected with the opening containing the valve arrangement and extendingfto the bottom of the container or an inverted system without a dip-tube may be'-used.-- Upon opening the valve the composition is expelled through the opening in the form of a fine stream to form an aerosol of the medicament. Toaccomplish suitable aerosolization of the medicatnent the opening is desirably constructed to provide a small orifice so as to expel a fine spray of the composition., The container just described is typical of thesecalled aerosol bomb. One typical form of device which iseminently satisfactory for dispensing accurately measured quantities of the medicament in a suitable aerosol form and insuring eflective administration is that disclosed in our copending' application entitled, Aerosol Dispensing Apparatus, Serial No. 572,965,--filed concurrently with this application. I "The terms and expressions which we have employed are used as terms-of description and not of limitation, and we have no intention, in the use of suchterms and expressions, of excluding any equivalents of the features shown and described or portions thereof, but recognize that various modifications are possible within the scop of the invention claimed.

, .What is claimed is: a

1. A self-propelling pharmaceutical composition capable of providing a medicament in aerosol formsuitable for inhalation therapy, comprising as the medicament a water-soluble acid-addition salt of a bronchodi lator amine selected from the class consisting of isoproterenol and epinephrine, said medicament comprising between about 0.1% and 2% of the composition, as a co solvent for said medicament, an aqueous ethanol mixture in an amount comprising between about 20% to 40% of the composition, the water in said cosolvent comprising between about 1.5% and 2% 'of the total com'-' position, and as a liquefied non-toxic propellant componut 21 halogenated lower alkane containing at least 1 fluorine atom and not more than 2 carbon atoms and having a vapor pressure of between about 20 and 65 pounds per square inch gauge at F., said liquefied propellantfcomponent comprising substantially the re mainder of the composition.

2.- A self-propelling pharmaceutical composition as defined by claim 1, wherein the liquefied non-toxic propellantcomponent comprises a mixture of said halogenated lower alkanes.

3. A self-propelling pharmaceutical composition as defined by claim 1, wherein the liquefied non-toxic propellant component has a vapor pressure of between about a 20 and 40 pounds per square inch gauge at 70 F.

4. A self-propelling pharmaceutical composition as defined by claim I, wherein the liquefied non-toxic propellant component is selected from the group consisting of dichlorodifluoromethane and a mixture of dichlorodifiuoromethane and dichlorotetrafiuoroethane.

'5. A self-propelling pharmaceutical composition as deinedby c im. 1, whe e h m c m compr se a water s'oliibleiacid addition salt of epinephrine.

Aseiep o onia pharmaceutical composition as defined by claim 1, wherein the medicament comprises isoproterenol hydrochloride.

,8 A s lfr e lin ha a tica c m osi as. efi y fs i .1. he e n th h q sam nt om ses epinephrine hydrochloride.

se -swellin Ph r aceut ca o po t on si efined by claim '1, containing about 0.2% isoproterenol hydrochloride, about 2% wate about 37.8% ethanol, 3 91 .39 li uefied tsi hls qmh ofluorom hane. and shq li e i d. is lomdiflu sm th .A- Ql -Pmps in pharm seu l mp sition as defined'by claim 1, containing about 0.25% epinephrine, about 0.5%,oj a 3% .normal solution ofhydrochloric acid, about 0.15% ascorbic acid, about; 1% a ditional-water, about 33. 1%, ethanol, about 25% liquefiedv dichlorodisfiuoromethane, and about 40% liquefied ,dichlorotetra: fluoroethane.

11 A self-propelling pharmaceutical composition as defined by claim .1 containing about 0.25% ,isoprotera enol hydrochloride, about-1.5% water, about 33.25%- ethanol, and the remainder being a liquefied'non-toxie propellant as ,defi ne d by claim 1.

12. Asel-f-propelling pharmaceutical composition as definedby claim 11, containing about 0.25%l.isoproter-. enol hydrochloride, about 1.5% water, about "33.25% ethanol, and the remainder being liquefied dichlorodifluoromethane. i 13. A self-propelling pharmaceutical composition as defined by claim 11, containing about 0.25% isoproterenol hydrochloride, about 1.5 water, about 33.25% ethanol, about 40% liquefied dichlorotetrafiuoroethane, and-about 25% liquefied dichlorodifluoromethane. V

14. A package comprising a pressure-tight container having a valve-controlled opening and containing a selfpropelling pharmaceutical composition capable of providing a medicament in aerosol form suitable forinhal-ation therapy, comprising as a medicament a water-soluble acid-addition salt ofa bronchodilator' amine selected from the. class consisting of. isoproterenol and epinephrine,- said medicament comprising between about 0.1% and 2% of the composition, as. a .cosolvent-for said medicament an aqueous ethanol mixture. in an. amount comprising- -betwee about 20%. and 40% of the composition, the waterin said cosolvent comprising between about 1.5% and 2% of the total. composition, and as a liquefiedinontoxic propellant component a halogenated lower allgane containing at least '1 fluorine atom and not more that-n2 carbon atoms and. having a vapor pressure ofbetween abqutZO: and 65 pounds per square inch gauge at- 70" =F.',

8 said liquefied propellant component comprising substantia l lythe remainder of the composition.

15. A method oi producing a measured dose ofimedicament in aerosol form suitable for inhalation therapy whi omprise f rm n a q d mposition oira' msdis mentqnthetorm o a atqrs luhleaci d ition altof abronchodilatoramine selected from the class consisting otisoproterenol and epinephrine, said medicamom. comprising between about 0.1% and 2% of the composition, said medicament being dissolved ina mixture of a co-solvent and a liquefied non-toxic propellant component, said co-solvent comprising an aqueous ethanol gniggtpre i n an amount comprising between about 2 1 and 49% oi the total. c mpos the Waterfih said nqns9lve n t comprising between about l.5'%.wand'2%' or the total composition, said liquefied non-toxic; propellant component comprising a halogenated lower alkane containing at least 1 fluorine atom and not more than 2 carbon atoms and having a--.v-ap,or pressure of between ab9u-t'20 and pounds per square inch gauge at F., said liquefied propellant component comprising substan-v a ly e .remainder ofthe. composition,v .and dispensing he. l iq isl .qq l position. from. a. pressure-tight. container through a control valve for-self-propelled delivery in the f rm of an. a lQS01' l'QSU1l1l1g from the rapidvaporization of...the propellant.

References Cited in thefile 'of this patent UNITED STATES PATENTS 2,232,976- Fox Nov. 26,1240,

Fulton: Propellents for Low-Pressure Liquefied Gas Aerosols, Ind. and Eng. Chem, vol. 40, No. 4, April 1948, pp. 699 and 700.

Fulton: Germicidal Aerosols, Soap and Sanitary Chemicals, May 1948, pp. -127, 157 and 1 59..

Mina-z Glass-Aerosols for Cosmetics, Amer. Peri. and'EsscOil Rev- Iune 1954, pp. 429-31;

Downing:- Formulation of- Aerosol Products, Soap and; Sanitary Chem., September 1953, pp. 142, 143, 145, 147; 149, 153, 155, 177 and 178.

U. S. Disp., 25th Ed., J; B. Lippincott Co., pp. 38 and 39,- Philadelphia, Pa.

Drugand Cos. Ind., vol. 65, No. 4, October 1949,. pp, 396-98-and- 470-73. I

New'and- Non-oificial Remedies, J. B; Lippincott Co.,v Philadelphia, Pa., 1955, pp. 225-227;

Merck Index, 6th ed., Merck and Co., Inc., 1952, pp. 72, 73, 387-89, 664 and, 674-75..

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2222976 *Nov 15, 1937Nov 26, 1940Sharp & Dohme IncNasal drops
US2728495 *Apr 19, 1951Dec 27, 1955Little Inc ALiquid dispensing device and composition therefor
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3039928 *Mar 17, 1960Jun 19, 1962Abbott LabStable aqueous isoproteronol compositions
US3039929 *Mar 17, 1960Jun 19, 1962Abbott LabStable isoproteronol compositions
US3050443 *Feb 16, 1960Aug 21, 1962James F SchuylerHeadache remedy containing ammonia
US3051621 *Oct 22, 1959Aug 28, 1962Grove Lab IncGel composition, pressurized container with same, and method of preparation
US3088874 *May 23, 1960May 7, 1963Union Carbide CorpPowder aerosol
US3155574 *May 24, 1962Nov 3, 1964RevlonAerosol composition
US3169095 *Oct 30, 1962Feb 9, 1965Rexall Drug ChemicalSelf-propelling powder-dispensing compositions
US3282781 *Nov 25, 1960Nov 1, 1966Merck & Co IncInhalant compositions
US3341604 *Jan 28, 1963Sep 12, 1967Exxon Research Engineering CoColor stable ketone solvent composition
US3710782 *Oct 1, 1969Jan 16, 1973Hauser Res And Eng CoMethod of treating human skin with a composition for electromedical applications
US4352789 *Mar 17, 1980Oct 5, 1982Minnesota Mining And Manufacturing CompanyAerosol compositions containing finely divided solid materials
US4576949 *May 7, 1984Mar 18, 1986The Upjohn CompanyUse of 5,6,7,8-tetrahydroquinolines and 5,6-dihydropyrindines as leukotriene and lipoxygenase inhibitors and the novel 3-substituted compounds therein
US4919919 *Sep 14, 1988Apr 24, 1990Nippon Kayaku Kabushiki KaishaNitroglycerin spray
US5118494 *Mar 13, 1991Jun 2, 1992Minnesota Mining And Manufacturing CompanyUse of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5175152 *Sep 28, 1990Dec 29, 1992Singh Nikhilesh NTreating respiratory system disorders
US5225183 *Jan 30, 1991Jul 6, 1993Riker Laboratories, Inc.Medicinal aerosol formulations
US5292884 *Oct 13, 1992Mar 8, 1994Biomide Investment Limited PartnershipCyclic hydroxamic acids
US5439670 *Jul 2, 1993Aug 8, 1995Riker Laboratories, Inc.Self-propelling bronchodilator agents substantially free of chlorofluorocarbons
US5514713 *Dec 2, 1994May 7, 1996Ono Pharmaceutical Co., Ltd.Antiinflammatory agents, antiallergens
US5534536 *Aug 23, 1994Jul 9, 1996Ono Pharmaceuticals Co. Ltd.Inhibitors of thromboxane a2 synthetase, 5-lipoxygenase; scavengers of active oxygen species
US5605674 *May 31, 1995Feb 25, 1997Riker Laboratories, Inc.Medicinal aerosol formulations
US5653962 *May 19, 1995Aug 5, 1997Glaxo Group LimitedAerosol formulations containing P134a and particulate medicaments
US5658549 *May 19, 1995Aug 19, 1997Glaxo Group LimitedInhalating drug comprising tetrafluoroethane/1,1,1,2-/ for treating respiratory system disorder
US5674471 *May 19, 1995Oct 7, 1997Glaxo Group LimitedAerosol formulations containing P134a and salbutamol
US5674472 *May 19, 1995Oct 7, 1997Glaxo Group LimitedDrug delivery
US5674473 *May 31, 1995Oct 7, 1997Riker Laboratories, Inc.Medicinal aerosol formulations
US5676929 *May 19, 1995Oct 14, 1997Glaxo Group LimitedCanister containing aerosol formulations containing P134a and particulate medicaments
US5679287 *Apr 28, 1995Oct 21, 1997Great Lakes Chemical CorporationUses of heptafluoropropane
US5681545 *May 31, 1995Oct 28, 1997Riker Laboratories, Inc.Charging aerosol container with a medicament and propellent selected from 1,1,1,2-tetrafluoroethane free of chlorofluorocarbons, dispersing said medicine, suitable for delivery to lungs by inhalation
US5683676 *May 19, 1995Nov 4, 1997Glaxo Group LimitedCanister containing aerosol formulations containing P134a and particulate medicaments
US5683677 *May 31, 1995Nov 4, 1997Riker Laboratories, Inc.1,1,1,2-tetrafluoroethane; chlorofluorocarbon-free; self-propelling
US5695743 *Mar 4, 1993Dec 9, 1997Riker Laboratories, Inc.Medicinal aerosol formulations
US5720940 *May 31, 1995Feb 24, 1998Riker Laboratories, Inc.Medicinal aerosol formulations
US5736124 *May 30, 1995Apr 7, 1998Glaxo Group LimitedAerosol formulations containing P134a and particulate medicament
US5744123 *Jun 5, 1995Apr 28, 1998Glaxo Group LimitedAerosol formulations containing P134a and particulate medicaments
US5750544 *Apr 19, 1996May 12, 1998Ono Pharmaceuticals Co., Ltd.Cardiovascular disorders; antiischemic agents; brain disorders; antiasthma agents; antiinflammatorey agents; antiulcer agents; skin disorders; antallergens
US5766573 *Jan 16, 1997Jun 16, 1998Riker Laboratories, Inc.Delivering aerosol drug formulation from container using 1,1,1,2-tetrafluoroethane propellant
US5776432 *May 31, 1995Jul 7, 1998Minnesota Mining And Manufacturing CompanyTreating asthma
US5776433 *May 31, 1995Jul 7, 1998Minnesota Mining And Manufacturing CompanySolutions for aerosols and propellants of tetrafluoroethane,heptafluoropropane and ethanol
US5785952 *May 12, 1995Jul 28, 1998Glaxo Group LimitedDry powders comprising drug and halohydrocarbon propellants for drug delivery
US5817293 *May 30, 1995Oct 6, 1998Glaxo Group LimitedCanister containing aerosol formulations containing P134a and particulate medicaments
US5840213 *Mar 14, 1997Nov 24, 1998Great Lakes Chemical CorporationUses of heptafluoropropane
US5861268 *May 23, 1996Jan 19, 1999Biomide Investment Limited PartnershipMethod for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase
US5891419 *Apr 21, 1997Apr 6, 1999Aeropharm Technology LimitedEnvironmentally safe flunisolide aerosol formulations for oral inhalation
US5891420 *Apr 21, 1997Apr 6, 1999Aeropharm Technology LimitedEnvironmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US5916540 *Apr 6, 1998Jun 29, 1999Glaxo Group LimitedAerosol formulations containing P134A and/or P227 and particulate medicament
US5919435 *May 12, 1995Jul 6, 1999Glaxo Group LimitedAerosol formulation containing a particulate medicament
US5922306 *Apr 15, 1998Jul 13, 1999Glaxo Group LimitedInhalants dispersion comprising tetrafluoroethane/1,1,1,2-/ propellant, drug particles precoated with surfactant, the drug formulation consists of betamethasone, ergotamine tartrate or sodium cromoglycate for respiratory system disorders
US5980867 *Jul 6, 1998Nov 9, 19993M Innovative Prperties CompanyAn inhalants comprising flunisolide, ethanol, and a propellant selected from 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane for treating bronchial asthma
US6022893 *Aug 7, 1996Feb 8, 2000Ono Pharmaceutical Co., Ltd.Hydroxamic acid derivatives
US6054488 *Jun 2, 1998Apr 25, 20003M Innovative Properties CompanyOr its acid addition salt containing ethanol and surfactantother than acetylated monoglycerides; no change crystalmorphology on storage; redispersible
US6129905 *Aug 13, 1997Oct 10, 2000Aeropharm Technology, Inc.Aerosol formulations containing a sugar as a dispersant
US6136294 *Sep 22, 1998Oct 24, 2000Aeropharm Technology Inc.Amino acid stabilized medical aerosol formulation
US6200549Mar 9, 1999Mar 13, 2001Glaxo Group LimitedContains less than 0.0001% w/w surfactant based upon the weight of medicament
US6221339May 10, 1999Apr 24, 2001Glaxo Group LimitedMedicaments
US6238647Nov 2, 1999May 29, 2001Glaxo Group LimitedAnticholinergic medicament which is selected from the group consisting of ipratropium, atropine, oxitropium and salts thereof
US6251368Jun 17, 1997Jun 26, 2001Glaxo Group LimitedAerosol drugs salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate and physiologically acceptable salts
US6303103Jun 14, 2000Oct 16, 2001Glaxo Group Limited1,1,1,2-tetrafluoroethane as propellant; inhalants.
US6306368Nov 24, 1998Oct 23, 2001Glaxo Group LimitedUse in administration of medicaments by inhalation
US6306369Apr 28, 2000Oct 23, 2001Glaxo Group LimitedComprising bronchodilatory agent, anti-infalmmatory agent and 1,1,1,2-tetrafluoroethane propellent; for administration of medicaments by inhalation; for therapy of respiratory system disorders
US6333023May 1, 2000Dec 25, 2001Glaxo Group LimitedFor therapy of respiratory disorders
US6346232Mar 29, 2000Feb 12, 20023M Innovative Properties CompanyAerosol formulation of beclomethasone-17,21-dipropionate, fluoroalkane propellants and ethanol
US6352684Apr 28, 1998Mar 5, 2002Riker Laboratories Inc.Nonionic surfactant; reduces ozone depletion potential
US6416743Aug 30, 2000Jul 9, 2002Schering CorporationNontoxic, stable formulation free of chlorofluorocarbons; surfactant and excipient free
US6458338Jul 17, 2000Oct 1, 2002Aeropharm Technology IncorporatedAmino acid stabilized medicinal aerosol formulations
US6461591Feb 2, 1998Oct 8, 2002Jago Research AgStorage stability
US6475467Aug 2, 1999Nov 5, 2002Jago Research AgMedicinal aerosol formulations
US6503482Jun 8, 1992Jan 7, 2003Schering CorporationNon-chlorofluorocarbon aerosol formulations
US6585958Jul 22, 1999Jul 1, 2003Jago Research AgMedicinal aerosol formulations
US6743413May 31, 1995Jun 1, 20043M CompanySuspension aerosol formulations
US6893628Mar 31, 2003May 17, 2005Glaxo Group LimitedAerosol formulations containing P134a and particulate medicament
US6919069Apr 30, 2003Jul 19, 2005Glaxo Group LimitedAerosol formulation containing particulate formoterol, propellant and polar cosolvent
US7101534May 31, 1995Sep 5, 20063M Innovative Properties CompanySuspension aerosol formulations
US7105152May 31, 1995Sep 12, 20063M Innovative Properties CompanySuspension aerosol formulations
US7176240Jul 15, 2002Feb 13, 2007Ono Pharmaceutical Co., Ltd.Such as 5-fluoro-2-propylpentanoic acid for improving GABA (gamma-aminobutyric acid) receptor responses; treatment of neurodegenerative diseases
US7498020Nov 23, 2004Mar 3, 2009Glaxo Group LimitedMedicaments
US7566445Jun 4, 1997Jul 28, 2009Norton Healthcare LimitedCanister comprising container closed with metering valve, comprising pharmaceutical suspension aerosol formulation free of surfactant, which consists of salbutamol sulphate, ethanol, and 1,1,1,2-tetrafluoroethane; higher levels of ethanol have beneficial results
US7569608Jul 29, 2005Aug 4, 2009Ono Pharmaceutical Co., Ltd.Pentanoic acid derivatives
US7569609Jul 29, 2005Aug 4, 2009Ono Pharmaceutical Co., Ltd.Treating Alzheimer's disease with 2-propylpentanoic acid (valproic acid) or salts thereof; improving the GABAA receptor responses
US7582284Apr 14, 2003Sep 1, 2009Nektar TherapeuticsActive substances in particulate form, to methods for preparing them, to formulations containing them and to uses of such substances and formulations. A preferred embodiment is directed to particulate suspensions having improved
US7994197Aug 26, 2009Aug 9, 2011Map Pharmaceuticals, Inc.Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US8080236Jun 12, 2009Dec 20, 2011Nektar Therapeutics Uk, LtdParticulate materials
US8119639Jul 19, 2010Feb 21, 2012Map Pharmaceuticals, Inc.Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US8148377Feb 11, 2008Apr 3, 2012Map Pharmaceuticals, Inc.Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US8357393Dec 7, 2004Jan 22, 2013Acrux Dds Pty Ltd.drug and a dermal penetration enhancer that form an amorphous deposit upon evaporation of the volatile carrier to control the extent and/or profile of transdermal release of a drug
US8357696Jan 28, 2010Jan 22, 2013Mpex Pharmaceuticals, Inc.Aerosolized fluoroquinolones and uses thereof
US8470301Nov 11, 2011Jun 25, 2013Nektar TherapeuticsParticulate materials
US8524734Oct 22, 2009Sep 3, 2013Mpex Pharmaceuticals, Inc.Aerosolized fluoroquinolones and uses thereof
US8524735Oct 22, 2009Sep 3, 2013Mpex Pharmaceuticals, Inc.Aerosolized fluoroquinolones and uses thereof
US8546423Oct 22, 2009Oct 1, 2013Mpex Pharmaceuticals, Inc.Aerosolized fluoroquinolones and uses thereof
US8629139Oct 6, 2009Jan 14, 2014Mpex Pharmaceuticals, Inc.Topical use of Levofloxacin for reducing lung inflammation
US8722340Oct 18, 2007May 13, 2014Board Of Regents, The University Of Texas SystemJAB1 as a prognostic marker and a therapeutic target for human cancer
US8784878Dec 11, 2012Jul 22, 2014Acrux DDS Pty Ltc.Transdermal delivery rate control using amorphous pharmaceutical compositions
US8815838Oct 6, 2009Aug 26, 2014David C. GriffithAerosol fluoroquinolone formulations for improved pharmacokinetics
US8828359Jun 3, 2013Sep 9, 2014Nektar TherapeuticsParticulate materials
US8834849May 29, 2009Sep 16, 2014Norton Healthcare LimitedMedicinal aerosols and methods of delivery thereof
US8853277Nov 30, 2010Oct 7, 2014The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesNitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC)
US20120316246 *Jul 17, 2012Dec 13, 2012Fahl William ETopical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
DE2703119A1 *Jan 26, 1977Aug 4, 1977Fisons LtdDinatriumcromoglycat mit weniger als 5 % wasser und dieses umfassende pharmazeutische praeparate
DE2831419A1 *Jul 18, 1978Feb 1, 1979Fisons LtdAerosol compsn., pref. contg. fine medicament
DE102008007198A1Feb 1, 2008Aug 13, 2009Infectopharm Arzneimittel Und Consilium GmbhOral oder nasal applizierbare Epinephrin- haltige Zubereitungen mit verbesserten Eigenschaften
EP0148748A2 *Jan 4, 1985Jul 17, 1985Ab LeoImproved snuff and preparation thereof
EP0213108A2 *Jun 26, 1986Mar 4, 1987Kurt Dr. BurghartPharmaceutical preparation containing an antihypotonic as the active agent
EP0703216A1Sep 19, 1995Mar 27, 1996Ono Pharmaceutical Co., Ltd.Amidinophenol derivatives as protease inhibitors
EP0757037A2Jul 29, 1996Feb 5, 1997Ono Pharmaceutical Co., Ltd.Sulfonylamino acid derivatives as metalloproteinase inhibitors
EP2085071A1Jan 19, 2009Aug 5, 2009Infectopharm Arzneimittel und Consilium GmbHOrally or nasally administrable preparations containing epinephrine with improved characteristics
EP2206698A1Dec 21, 2009Jul 14, 2010ONO Pharmaceutical Co., Ltd.Ethynylindole compounds
EP2243493A1Jul 2, 2003Oct 27, 2010Ono Pharmaceutical Co., Ltd.Immunopotentiative composition
EP2253642A1Dec 25, 1998Nov 24, 2010ONO Pharmaceutical Co., Ltd.Polypeptides, cDNAs encoding the same and utilization thereof
EP2255829A2Jul 22, 2002Dec 1, 2010Ono Pharmaceutical Co., Ltd.Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient
EP2264059A1Dec 25, 1998Dec 22, 2010ONO Pharmaceutical Co., Ltd.Polypeptides, cDNAs encoding the same and utilization thereof
EP2270051A2Jan 22, 2004Jan 5, 2011Ono Pharmaceutical Co., Ltd.Antibody specific for human PD-1 and CD3
EP2281818A1Feb 18, 2003Feb 9, 2011Ono Pharmaceutical Co., Ltd.Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
EP2308562A2Dec 24, 2004Apr 13, 2011Ono Pharmaceutical Co., Ltd.Azetidine ring compounds and drugs comprising the same
EP2364982A1Apr 16, 2004Sep 14, 2011ONO Pharmaceutical Co., Ltd.Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof
EP2385040A1Mar 12, 2004Nov 9, 2011ONO Pharmaceutical Co., Ltd.Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
EP2422814A1Jul 23, 2004Feb 29, 2012Ono Pharmaceutical Co., Ltd.Remedy for cartilage-related diseases
EP2465537A1Oct 9, 2003Jun 20, 2012ONO Pharmaceutical Co., Ltd.Microspheres comprising ONO-1301
EP2465538A2Oct 20, 2005Jun 20, 2012Ono Pharmaceutical Co., Ltd.Use of immunesuppressant receptor
EP2481732A1Aug 31, 2004Aug 1, 2012Ono Pharmaceutical Co., Ltd.Condensed ring compound and use thereof
EP2508204A2Jun 25, 2003Oct 10, 2012Ono Pharmaceutical Co., Ltd.Remedies for diseases caused by vascular contraction or dilation
EP2565178A1May 28, 2003Mar 6, 2013Ono Pharmaceutical Co., Ltd.LPA Receptor Antagonists
EP2594272A2May 18, 2006May 22, 2013Mpex Pharmaceuticals, Inc.Aerosolized fluoroquinolones and uses thereof
EP2657235A1Oct 27, 2006Oct 30, 2013Ono Pharmaceutical Co., Ltd.Compound containing basic group and use thereof
WO1992005781A1 *Sep 26, 1991Apr 16, 1992Procter & GambleComposition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
WO1994013262A1 *Dec 6, 1993Jun 23, 1994Paul D JagerStabilized medicinal aerosol solution formulations
WO1994013263A1 *Dec 6, 1993Jun 23, 1994Paul D JagerStabilized medicinal aerosol solution formulations
WO1996033913A1 *Apr 26, 1996Oct 31, 1996Great Lakes Chemical CorpNovel uses of heptafluoropropane
WO2004031118A1May 28, 2003Apr 15, 2004Ono Pharmaceutical CoLpa receptor antagonists
WO2004032965A1Oct 9, 2003Apr 22, 2004Ono Pharmaceutical CoEndogenous repair factor production promoters
WO2005063704A1Dec 24, 2004Jul 14, 2005Ono Pharmaceutical CoAzetidine ring compounds and drugs comprising the same
WO2007049771A1Oct 27, 2006May 3, 2007Ono Pharmaceutical CoCompound containing basic group and use thereof
WO2007069565A1Dec 11, 2006Jun 21, 2007Yoshifumi KagamiishiBicyclic heterocyclic compound
WO2007069671A1Dec 14, 2006Jun 21, 2007Yoshifumi KagamiishiBicyclic heterocyclic compound
WO2008136377A1Apr 25, 2008Nov 13, 2008Yoshifumi KagamiishiBicyclic heterocyclic compound
WO2010147133A1Jun 16, 2010Dec 23, 2010Ono Pharmaceutical Co., Ltd.Novel imidazopyridine compound
WO2011066537A1Nov 30, 2010Jun 3, 2011The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesNitroxide therapy for the treatment of von hippel - lindau disease (vhl) and renal clear cell carcinoma (rcc)
WO2011162222A1Jun 20, 2011Dec 29, 2011Ono Pharmaceutical Co., Ltd.Novel crystalline forms of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1h-indole-1,3-diyl]dibutanoic acid, 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutanoic acid, and 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutanoic acid
WO2012074069A1Dec 1, 2011Jun 7, 2012Ono Pharmaceutical Co., Ltd.Novel compound and medical use thereof
WO2012127885A1Jan 5, 2012Sep 27, 2012Ono Pharmaceutical Co., Ltd.Tetrahydrocarboline derivative
WO2013161919A1Apr 25, 2013Oct 31, 2013Ono Pharmaceutical Co., Ltd.Trk-INHIBITING COMPOUND
U.S. Classification222/192, 514/653, 514/645, 424/45, 222/394, 514/343, 514/304
International ClassificationC09K3/30, A61K9/00, A61K31/16, B05B9/00
Cooperative ClassificationA61K9/008
European ClassificationA61K9/00M20B6